Your session is about to expire
← Back to Search
Glutamine PET Imaging for Head and Neck Cancer
Phase < 1
Waitlist Available
Led By Lesley Flynt, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
≥18 years of age
Pathologically or cytologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
Study Summary
This trial will study whether a new cancer imaging technique is effective and safe in 20 patients with head and neck squamous cell carcinoma.
Who is the study for?
This trial is for adults over 18 with confirmed head and neck squamous cell carcinoma (HNSCC) who can consent to the study. They must have measurable disease by specific criteria and be able to undergo CT or MRI scans. Pregnant or breastfeeding individuals, those allergic to IV contrast, with poor kidney function, or too large for imaging equipment are excluded.Check my eligibility
What is being tested?
The study tests two PET/CT imaging agents, 11C-Glutamine followed by 18F-FSPG, in patients with HNSCC. It aims to evaluate these tracers' effectiveness in measuring tumor uptake of glutamine and gather additional safety data on their use.See study design
What are the potential side effects?
So far, no adverse side effects have been observed from using the tracer agents as they are naturally occurring amino acids given at low doses not expected to cause toxicity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
My cancer is a type of head and neck cancer confirmed by lab tests.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To establish the ability of 11C-Gln PET imaging to detect tumors in patients with (HNSCC) Head and Neck Squamous Cell Carcinoma NSCC.
Squamous cell carcinoma
Trial Design
1Treatment groups
Experimental Treatment
Group I: PET scanExperimental Treatment2 Interventions
PET scans: an 11C-Glutamine PET scan and an 18F-FSPG PET scan. A small tube (called an IV) will be placed in a vein in your arm through which you will receive the radioactive material for the PET scan(s).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Florilglutamic acid F-18
Not yet FDA approved
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,976 Previous Clinical Trials
1,789,505 Total Patients Enrolled
Lesley Flynt, MDPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
120 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not speak English but can give consent with a translated form.I have had (or will have) a CT or MRI within the last 42 days.I weigh over 400 pounds or have a condition that prevents me from undergoing certain scans.I am 18 years old or older.My cancer is a type of head and neck cancer confirmed by lab tests.
Research Study Groups:
This trial has the following groups:- Group 1: PET scan
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger